To study whether adding topical steroid eye drops to the standard of care in acanthamoeba keratitis aids in the healing of the conditio
Phase 3
- Conditions
- Health Condition 1: H188- Other specified disorders of cornea
- Registration Number
- CTRI/2024/02/062387
- Lead Sponsor
- ational Institute of Health-National Eye Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
a) Smear culture PCR Confocal positive Acanthamoeba keratitis
b) Acanthamoeba keratitis patients treated with antiamoebic therapy and have corneal episcleral or anterior chamber inflammation at 4 weeks
c) Appropriate written and informed consent
Exclusion Criteria
a) No consent
b) Fungal or Herpetic keratitis
c) Corneal perforation and impending corneal perforation
d) Prior keratoplasty
e) Visual acuity of No light perception in the affected eye
f) Debilitated patient
g) Patients on systemic corticosteroids
h) Corticosteroids allergy
i) Pregnant mothers
j) Steroids responders
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improved 6 month best corrected visual acuity and hasten the time for acanthamoeba keratitis clinical resolution in the steroid groupTimepoint: 4 years
- Secondary Outcome Measures
Name Time Method To study the contribution of organism virulence factors and host factors for severe inflammatory outcomes by metagenomic deep sequencingTimepoint: 4 years